BTIG Maintains Buy on RxSight, Raises Price Target to $73
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Buy rating on RxSight (NASDAQ:RXST) and raises the price target from $72 to $73.
July 15, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman has maintained a Buy rating on RxSight and increased the price target from $72 to $73.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100